A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy
Clinical trial NCT03301207 · COMPLETED
Trial details
- NCT number
- NCT03301207
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-10-20
- Primary completion
- 2018-07-17
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.